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Abstract 
 
Background: Most breast cancers in Oman are diagnosed at advanced stages and therefore early 
detection is important. The Oman Cancer Association (OCA) initiated a mobile mammography 
program in 2009 but no studies have evaluated the impact of the program. This study aimed to 
estimate the proportion of OCA-screened women who had repeated mammography (compliance) 
and the associated predictors. The sensitivity and specificity of the program were also evaluated.   
  
Methods: Data for 13,079 women screened in the mammography clinic of OCA from 2009-
2016 and medical records of all breast cancer patients seen at Royal and Sultan Qaboos 
University hospitals during the same period were retrieved and abstracted.  Data included 
demographics and screening results from OCA and diagnosis and treatment from the two 
hospitals. Logistic regression analysis was conducted to identify predictors of compliance.   
Results: A total of 8,278 screened women over age 42 years were in the study (median age 50 
years, standard deviation (SD) 8 years). Only 18% of screened women were compliant with 
mammography screening.  Predictors of compliance included age 50-69 years, family history of 
cancer, family history of breast cancer, and breast self-examination. The cancer detection rate 
was 4.1/1000 screened women. Positive predictive value of screening mammography was 4.7% 
with a sensitivity rate of 53% and specificity of 92%.   
 
Conclusion: This study showed low mammography compliance rate among previously screened 
women. The study revealed low sensitivity, high specificity, and acceptable cancer detection 
rate.  Future programs should focus on improving data collection for screened women, initiating 
linkage of databases between breast cancer screening and treatment clinics, and developing 
guidelines and policies for breast cancer screening in Oman.  
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Background: 
Cancer is a global disease affecting women in developed as well as developing countries with 
expected rise of the disease burden from 14.1 million in 2012 to over 20 million patients per 
annum by 2025 (Ferlay et al., 2015). With increasing life expectancy in the developing countries, 
the burden of cancer is expected to increase. Approximately 8.8 million deaths worldwide were 
cancer-related in 2015 and 70% of cancer mortality occurred in low and middle-income 
countries (Fitzmaurice et al., 2017). Breast cancer is the most common cancer among women 
globally and its proportion to all cancers jumped from 11 % in 2008 to 12 % in 2012 (Tao et al., 
2015).  In 2015, breast cancer mortality represented 15% of all cancer-related deaths among 
women (World Health Organization, 2017). Although breast cancer is thought to be a disease of 
the developed world, over half (52%) of breast cancer cases occur in less developed countries 
(DeSantis et al., 2015). Furthermore, breast cancer survival tends to be poorer in developing than 
developed countries because of delayed diagnosis, limited availability of screening programs, 
and limited access to treatment (Siegel et al., 2012).      
Patient timeliness is one of the most important factors for successful breast cancer management 
and survival (Tarver, 2012). Early detection and diagnosis with early intervention and follow-up 
play key factors in determining patient breast cancer survivorship. The survivorship rate of breast 
cancer increases to 98% if the disease is diagnosed at early stages and survivorship drops to 84 
% if the disease is diagnosed at regional stages (Miller et al., 2016; Tarver, 2012). Delay in 
breast cancer diagnosis and treatment has its significant impact on lowering survival rates and 
diminishing quality of life (Caplan, 2014). 
The Sultanate of Oman is located in the southeastern coast of the Arabian Peninsula and shares 
borders with Saudi Arabia, United Arab Emirates, and Yemen.  The native population of Oman 
is 2.5 million individuals in addition to 2.3 million expatriates (NCSI, 2017). Breast cancer 
accounts for approximately 32% of the total cancers among females in Oman (Renganathan et 
al., 2014) and 25% of patients are under the age of 39 years (Mehdi, I. 2014). The World Health 
Organization cancer country profiles for 2014 showed breast cancer as the leading cause of 
cancer-associated mortality in women in Oman with 18.0% proportional mortality ratio of all 
cancer-related deaths (WHO, 2014). With an overall improvement in 5-year breast cancer 
survival rate (from 64% to 78%) in Oman from 1996 to 2008 (Kumar, Burney, Al-Ajmi, & Al-
Moundhri, 2011), there has been no change in younger age and advanced stage at presentation 
[stages III (41.2%) and IV (18.2%)] in the same period (Al-Moundhri, 2013).  
The Oman Cancer Association (OCA) is a non-governmental non-profit organization dedicated 
to increasing public awareness and educating cancer patients and their families. In 2009, OCA 
introduced a mobile mammography clinic as the first mobile screening program that travels all 
over the country offering free mammography and referral of suspected cases to the Royal 
Hospital (RH). The RH is one of the 2 tertiary referral hospitals that provide cancer treatment in 
the country (Ministry of Health, 2017). Since the inception of the OCA program, more than 
15,000 women have been screened and around 1,470 suspected cases were referred for further 
diagnostic investigations such as ultrasound testing, fine needle aspiration, and tissue biopsies. 
Although this program has been ongoing for almost a decade, no studies have been conducted to 
evaluate the experience of the OCA screening and awareness programs. Therefore, this study 
aimed to estimate the proportion and predictors of the OCA-screened women who had repeated 
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mammographic examination and to examine the sensitivity and specificity results among the 
cohort of the OCA-screened women.  
 
Methods:  
Study population: 
Data for this study was obtained from 3 sources: a) the mobile screening clinic of the OCA, b) 
the medical records of breast cancer patients diagnosed and/or treated at the RH, and c) the 
medical records of breast cancer patients diagnosed and/or treated at Sultan Qaboos University 
Hospital (SQUH).  The RH and SQUH are the only 2 tertiary hospitals that provide 
comprehensive cancer treatment in the country.   
 
The OCA database:  
Data of the 13,079 OCA-screened women from 2009 to 2016 was used for the current study. 
Inclusion in this study was limited to Omani women with no previous diagnosis of breast cancer, 
and those who had no pain, discharge, or palpable breast masses by history or on physical 
examination at the time of screening. Considering these inclusion criteria, a total of 8,278 
screened women were included and 720 of them had suspected results and were referred to the 
RH for further evaluation. We restricted our study to women over the age of 42 years to ensure 
sufficient time for women to have a second mammogram (we are looking for the second 
mammogram after the first one that should have been done at age 40 at least) and to increase the 
chance of women to catch the unit as the OCA mobile unit visit each place once per year. We 
also restricted the study to women of Omani nationality because many non-Omanis do not have 
medical insurance and are more likely to receive cancer treatment outside Oman. To allow for 
adequate time for breast cancer to be reported to a tumor registry after a suspected 
mammography, we included only women who were screened from January 2009 to December 
2016.   
The OCA patient history database is composed of demographic and medical history as well as 
mammography results of all women screened through the OCA screening program.  The patient 
history database is populated by data of self-administered questionnaires for women who can 
complete the questionnaires or interviewer-administered questionnaires, for illiterate screened 
women. The questionnaire included 40 questions about demographic, reproductive, family 
history of cancer, and breast cancer screening history questions which included frequency and 
date of screening.  Results of initial screening examinations were classified as negative for 
cancer or suspected and referred. In the OCA mammography database that used the BI-RADS 
classification, findings were considered negative for cancer if classified as category 1 or category 
2. Examinations reported with any of the following BI-RADS assessments were categorized as 
suspected and referred: category 0, category 3, category 4, and category 5.   
 
 
The RH and SQUH databases:  
The databases of the RH (1,153 cases) and the SQUH (810 cases) included data for 1,963 breast 
cancer patients diagnosed between January 2009 and December 2016. Electronic medical records 
were retrieved from both hospitals to obtain demographic characteristics (national ID, age, place 
of residence, and marital status) and date of breast cancer diagnosis. The data from 2 hospitals 
were compiled into one Excel file.  
Using national ID, place of residence, and 100% name match, the databases of OCA and 
 4 
the two hospitals were merged to identify breast cancer patients who were referred from the 
OCA screening program and breast cancer patients referred from any other screening or 
diagnostic services.  
The OCA patient history and examination forms included a consent that was signed by all 
women included in this study to use the data for research. The study was reviewed and approved 
by the institutional review boards at the University of Nebraska Medical Center, the Royal 
hospital, and the SQUH.   
 
Data management and statistical analysis: 
Repeated screening (compliance) was defined in this study as more than one screening. The 
definition was based on a previous study (Brown, 2006).  However, since the OCA database 
included screened women only, we modified the definition to more than one screening, 
regardless of the period between the screenings.  
 
True negative was defined as breast cancer not diagnosed within 2 years of a normal 
mammography result. False negative was defined as breast cancer diagnosed within 2 years of a 
normal mammography result. Women who received normal mammography results and later no 
record was found regarding their breast conditions in these 2 hospitals were considered as true 
negatives as well.  Patients screened at OCA and found to have abnormal mammography 
followed by histopathologic confirmation, within 2 years from the abnormal mammography, 
were considered true positives. If breast cancer was not diagnosed within 2 years of an abnormal 
mammography, the examination was considered false positive. The diagnosis date was the date 
at which the patient was assigned an ICD code for diagnosis of breast cancer in the RH or SQUH 
registration records.       
 
The sensitivity of mammography was calculated as the number of true-positive examinations 
divided by the number of true-positive plus false-negative examinations. The specificity of 
mammography was calculated as the number of true-negative examinations divided by the 
number of false-positive examinations plus the number of true-negative examinations. The 
positive predictive value was calculated as the percentage of women with abnormal OCA 
mammography results who were diagnosed later as cases of breast cancer within 2 years of the 
screening examination. Cancer detection rate was calculated as the number of true positive 
examinations divided by the total number of screening mammograms per 1000 examinations.  
 
Descriptive statistics were calculated using the PROC FREQ procedure and the variables were 
tested for significant association to screening compliance with the chi-square test. Logistic 
regression analysis was performed to identify predictors of screening compliance. We included 
in the model, the variables that show significant results in chi-square test (P values < 0.05). The 
dependent variable was screening compliance and the independent variables included age, family 
history of cancer, family history of breast cancer, and breast self-examination. Odds ratios and 
95% confidence intervals were calculated from the logistic regression model and p values for 
significance were defined as less than 0.05 for all the analyses which were performed using SAS 
statistical package version 9.3 (SAS, Inc. Cary, NC).      
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Results: 
Characteristics of the screened women in the OCA program are reported in Table 1.  A total of 
8,278 screening examinations were performed from 2009 to 2016. The median age of the 
screened women was 50 years (standard deviation (SD) 8 years). The largest proportion of 
women screened was in the age group 50–69 years (51%). Out of 8,278 screening 
mammography examinations, 8.6% were performed for women with a family history of breast 
cancer. Only 19.5% of screened women performed breast self-examination. Out of 8,278 
screened women, 9.7% and 3.8% reported a history of contraceptive use and surgical removal of 
the ovaries, respectively.  Table 1 summarizes the characteristics of referred versus non-referred 
women.  Among women who were screened and referred, 12% had a family history of breast 
cancer. Most referred women were in the age group 42-49 (51%) followed by women in the age 
group 50-69 (47%). The smallest proportion of referred women (2%) was in 70+ -year age 
group. The proportion of women with abnormal mammographic examination results was higher 
among women with no history of breast self-examination than among those who performed 
breast self-examination (80% versus 20%, for the 2 groups respectively).  Additionally, breast 
self-examination, contraceptive use, and history of oophorectomy were not significantly 
associated with referrals after suspected mammography (p>0.05).     
 
Prevalence of previous mammography for the total population is presented in Table 2. Among 
the 6,547 (82%) screened women who had not received a mammogram, 34% of them had family 
history of cancer, with 19% of them had family history of breast cancer. Only 18% of screened 
women reported having mammography more than once. Previous mammography was higher 
among women with no family history of cancer (66%) than those with family history of cancer 
(34%) (p<.0001). Higher compliance rates were also more likely in age group 50-69 than among 
women in other age groups (58%) (p<.0001). Women who were married had significantly higher 
compliance rates (80%) than non-married women, although the difference was statistically not 
significant (p>0.05). The proportion of women who had history of breast self-examination was 
higher among the compliant group (38%) than non-compliance group (15%) (p<.0001). 
 
Results of the multiple logistic regression analysis are reported in Table 3. Factors that predicted 
compliance included age, family history of cancer, family history of breast cancer, and breast 
self-examination.  When adjusting for all other factors, those in the 42–49 age group had 36.5 % 
lower odds of compliance as compared to women in the 50-69 age group (OR 0.64, 95% 
confidence interval (CI) 0.56-0.72, p>0.0001). Women in the 70+ age group also showed 43.5% 
lower odds of compliance than those in the age group of 50-69 (OR 0.57, 95% CI 0.37-0.87, 
p=0.01). After adjusting for all other factors, family history of cancer was significantly 
associated with compliance (OR 1.5; 95% CI 1.32-1.82, p>0.0001). Women with a history of 
breast self-examination had 3 times higher odds of compliance compared to those with no history 
of breast self-examination (OR 3.2, 95% CI 2.77-3.61, p>0.0001). Women with family history of 
breast cancer had 2 times higher odds of compliance compared to women without family history 
of breast cancer (OR 2.10, 95% CI 1.70-2.59, p>0.0001).   
 
Table 4 shows recall rate, sensitivity, specificity, and positive predictive value of the OCA 
screening program during the period 2009-2016. A total of 720 women were recalled and 
referred for further evaluation that translated to 8.7% recall rate. The largest proportion of 
women recalled in this study was in the age group 42–49 years (51%). A total of 34 breast cancer 
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cases were diagnosed by screening 8,278 women from 2009 to 2016. Thus, the cancer detection 
rate in this study was 4.1 per 1000 examinations. The positive predictive value of screening 
mammography was 4.7% with a sensitivity rate of 53% and specificity of 92%.  
 
 
 
Discussion:  
This study revealed the following interesting observations. First, the study showed a low overall 
rate of repeated mammography (compliance) in this population of screened women in Oman. 
Second, family history of cancer, family history of breast cancer, and history of self-breast 
examination were significant predictors of compliance. Third, the sensitivity of this screening 
program in Oman is lower than the sensitivity of other international programs but the specificity 
of the program was comparable to other international programs.  
 
Regarding the low rate of compliance shown in this study, it is important to report that no 
previous studies have been conducted on screening or compliance in Oman. Studies from Saudi 
Arabia showed variable rates of screening and compliance. For example, a longitudinal 
prospective study of 3778 Saudi women over the age of 40 years conducted in Riyadh reported 
the outcome of 7 years of follow-up (2007-2013) of the oldest breast cancer screening program 
in the country. The study showed 30% of mammography compliance (Abulkair et al., 2015). 
Another study conducted in Dammam included 8061 women over the age of 35 years screened 
between 2009 and 2014 by 2 mobile screening units of the Saudi Cancer Foundation showed 
only 3.0% of women reported having a second mammogram (Al Mulhim, Syed, Bagatadah, & 
Al Muhanna, 2015). However, studies from other Gulf countries showed results of ever-using 
mammography but no studies on repeated screening or compliance. For example, a cross-
sectional study of 519 women over the age of 20 years conducted in Kuwait showed 16.2 % rate 
of ever having a mammogram (Saeed, Bakir, & Ali, 2014). Another cross-sectional study of 
1063 Qatari and non-Qatari women over the age of 35 years showed 22.5% of the study 
participants ever having mammography (Donnelly et al., 2013).  
  
Studies from other Arab countries showed higher rates of compliance. A study conducted in 
Lebanon used data for the period 2005-2013 of 2400 women over the age of 40 years showed a 
compliance rate of 20.7% within the12 months following the initial screening (Haddad, Kourie, 
& Adib, 2015). A study from Jordan Jordan of 1549 women over the age of 18 years showed a 
compliance rate of 43.1% (Othman, Ahram, Al-Tarawneh, & Shahrouri, 2015).  In general, the 
overall compliance rates in Arab countries is lower than the rates in developed countries such as 
U.S. in which the compliance rate ranged between 50-70% (Puckett, Abedi, Alavi-Dunn, Hayes, 
& Garcia, 2016).  It also is important to note that mammographic screening programs in Arab 
countries, including Oman, are relatively recent (less than 15 years old).  Also, screening 
programs in Oman adopt opportunistic screening approaches. While population-based screening 
in Arab countries is not recommended because of low to moderate incidence of breast cancer 
(Harford, 2011), the situation in Oman is different.  Factors that make Oman different from low- 
and moderate-incidence developing countries include the relatively not uncommon young-onset 
breast cancer (25% of patients present under the age of 39), the advanced stage presentation 
(59% of cases are stages III and IV), the possible hereditary breast cancer genetics that need 
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further investigation in this population, and the fact that Oman has financial resources, and that 
the population size of Oman is relatively small (2.5 million individuals).  
   
Regarding the second observation of the predictors of compliance, it is noteworthy that the 
factors included in different studies to predict compliance varied between these studies. Some 
common variables in most of these studies included age, socioeconomic, and health insurance 
status of screened women, and whether or not primary care providers recommended screening. 
Age as a predictor of compliance in our study showed women in the age group 50-69 as the most 
compliant (58%) compared to other age groups [(40%) among the 42-49 age group and (2%) 
among the 70+ age group]. This finding was similar to other studies conducted in non-Arab 
countries.  For example, a prospective cohort study conducted among 8450 women who received 
a mammographic screening through mobile vans in Saint Louis, Missouri, showed that women in 
the age group 50-65 had higher odds of repeated visits to the mobile mammography van 
compared to women in the age group of 40-50 (Drake et al., 2015). This is an interesting 
observation since the median age of breast cancer in developed countries is higher than Oman 
but the compliant age groups are very similar between Oman and the U.S.  The higher rate of 
compliance among the age group of 50-69 might be due increased focus of women in this age 
group on chronic diseases than reproductive health.  Management of chronic diseases increases 
the possibility of multiple clinical visits and contact with clinical staffs, a variable found 
significantly associated with mammographic compliance in several studies (Peterson et al., 2016; 
Scheel et al., 2017). Unfortunately, information regarding provider-patient 
communication/recommendation was not included in the OCA breast examination form and 
accordingly we were not able to assess it.  For the age group under age 50, the low compliance 
might be due lack of feeling of breast cancer risk among this relatively young age group. A study 
of 1570 Hispanic women over the age of 40 years in the U.S. showed women under age 50 as 
non-adherent to mammography screening guidelines (Jones et al., 2017).  Lower utilization in 
the 70+ age group is probably due to women’s belief of their low risk for breast cancer in older 
age.  Lower utilization in the 70+ age group in this study was similar to a study conducted in 
Chile on 98 women over the age of 50. The study showed that women 65 years and older were 
less likely to comply with mammography screening recommendations than younger women 
(Wood, Vial, Martinez-Gutierrez, Mason, & Puschel, 2013).  Lower utilization in the 70+ age 
group also reported in the study described above from Lebanon (Haddad, Kourie, & Adib, 2015).        
 
Family history of breast cancer was a predictor of compliance in this study. Studies in the U.S. 
conducted in the 1990s on women 50 years and older showed family history of breast cancer as a 
significant predictor of screening mammography compliance (Lerman, Rimer, Trock, Balshem, 
& Engstrom, 1990). Another factor that predicted compliance in our study was breast self-
examination. However, most studies from developed countries did not show breast self-
examination as predictor of compliance but as a predictor of mammographic screening.  It is 
important to differentiate between our definition of compliance (ever repeated screening) and the 
definition of compliance/adherence in other studies (any mammography in last 2 years or 
following the guidelines of local mammographic screening).  Our results regarding the low 
compliance among screened women should be taken with caution because our definition of 
compliance is different from that in other studies. Also, we studied compliance among screened 
women while the vast majority of studies investigated compliance among general populations of 
non-screened women.  
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It is important to clarify that the term for suspected and referred cases in our study is equivalent 
to the term of recall rate used in other studies. Recall rate in other studies has been defined as the 
percent of screening mammograms that showed abnormalities and required further diagnostic 
procedures for confirmation (M. M. Bonafede, Miller, Huang, Troeger, & Fajardo, 2015; M. 
Bonafede, Miller, Lenhart, Nelson, & Fajardo, 2014). The recall rate in Gulf countries such as 
Saudi Arabia was reported from Riyadh as (6.8-10.9%) (Abulkair et al., 2015), Dammam as 
7.9% (Al Mulhim et al., 2015), and Jeddah as 13% (Baslaim, Baroum, Dashash, Al-Awwad, & 
Siddiqui, 2013). The American College of Radiology and the Agency for Health Care Research 
and Quality in the U.S. recommended recall rates of less than 10% (Rothschild, Lourenco, & 
Mainiero, 2013). The European guidelines for quality assurance in breast cancer screening and 
diagnosis also reported recall rates not higher than 7% as an acceptable rate for initial screening 
examinations (Perry et al., 2008).  However, U.S. and European screening programs show recall 
rates with a range of 1.3% to 18.4% which makes the 9% recall rate of the OCA comparable to 
international standards. Although the Omani rate in this study is comparable to other studies, we 
anticipated a higher recall rate in Oman than the observed rate in this study.  We also anticipated 
a higher Omani rate than the rates in developed countries. The reason for the anticipated higher 
rate is that the screening experience in this population is very recent and new screening programs 
are usually encountering symptomatic cases and act like diagnostic rather than screening 
programs. The lower than anticipated recall rate in this study might be due to our exclusion of 
symptomatic cases, the low incidence of breast cancer in Oman, and the low level of awareness 
about breast cancer and screening in this population (Al-Azri, Al-Hamedi, Al-Awisi, Al-Hinai, & 
Davidson, 2015; Albeshan, Mackey, Hossain, Alfuraih, & Brennan, 2017). We also anticipated a 
higher recall rate than the observed rate but the 9% recall rate in this study is considered within 
the recommended acceptable range of 5%–12% (Lehman et al., 2016). We used the Lehman et 
al., 2016 study for comparing our results as it is a benchmark for modern digital screening 
mammography in U.S. community practice.     
 
The cancer detection rate in this study was 4.1 per 1000 examinations, which is similar to a study 
conducted in Egypt on 20098 women over age 45 and showed a cancer detection rate of 4.3 per 
1000 screened (Salem et al., 2008). The cancer detection rate in this study is significantly higher 
than 3.5 cancers per 1000 examinations (a benchmark published by the U.S. National 
Mammography Database) but lower than the recent finding of 5.1 cancers per 1000 examinations 
in the Lehman et al., 2016 study. Although, the cancer detection rate in our study is lower than 
the recent finding of the Lehman et al., 2016 study, the OCA cancer detection rate is within the 
acceptable range of higher than 2.5 cancers per 1000 examinations.  The sensitivity level of 53% 
in this study was lower than the recent reported level of the Breast Cancer Surveillance 
Consortium (78.7%) and also lower than the acceptable sensitivity range of greater than 75% in 
U.S. (Lehman et al., 2016). The low level of sensitivity and expected recall rate in this study 
might be related to the inclusion of average risk group in OCA program. The specificity rate of 
92% in this study is comparable to the acceptable specificity range of 88%–95% in U.S. 
(Lehman et al., 2016).       
   
This study has several strengths. First, the study was the first investigation of any screening 
program in Oman. Second, the relatively long period (2009 to 2016) and large sample size of 
over 13079 add to power of the study. Third, the inclusion of women from capital city of Oman 
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and different geographic and remote area of country provided population representation of the 
country. Fourth, the inclusion of the two-tertiary hospitals for cancer management in the Oman 
maximized the opportunity for capturing all suspected breast cancer patients seen at OCA during 
the study period. However, the study had a few limitations. The study was limited by the use of 
self-reported history which could have introduced recall bias. Furthermore, we were unable to 
include data from other limited number of screening programs in Oman that could have given a 
broader picture of screening in the country. The hospital database variables required manual 
capturing which limited our ability to better investigate the comparison in stage and survival 
between screened and non-screened patients.   
 
In summary, this study showed low compliance rate among previously screened women of OCA. 
The study also showed that family history of cancer, family history of breast cancer, and breast 
self-examination are predictors of compliance. The study revealed low sensitivity, high 
specificity, and acceptable cancer detection rate.  Future programs should be directed into three 
channels. First, the OCA data collection process should be enhanced by tightening the number 
and quality of demographic and clinical questions on the breast history and examination forms. 
OCA should also put more emphasis on transforming the data entry and uploading the data into 
direct electronic databases. Second, RH and SQUH should enhance their medical record systems 
and make them more research oriented and accessible for linkage with the OCA. Third, the 
ministry of health should lead different groups dealing with breast cancer screening and 
management in Oman to develop national guidelines for breast cancer screening. These 
guidelines can address issues such as age limits of screening, frequency of screening, and 
integrating screening facilities and databases. This study demonstrates that OCA mobile 
screening program is an asset to remote geographic regions and communities with limited access 
to health care. More resources to expand this program will definitely has impact on increasing 
awareness and early diagnosis. This is demonstration of breast cancer screening programs in 
country with increasing incidence rate of breast cancer and emerging screening programs. The 
experiences of the OCA program and the lesion learned from evaluating it can be translated to 
other countries with similar condition of increasing cancer rate and consideration of screening 
program.   
	
	
	
	
	
Table 1. Characteristics of total papulation of 8,278 OCA-screened women, 7,558 screened not referred women and 720 screened and 
referred women included in the OCA screening program for period 2009-2016  
 
 a The X2 and p value results reflect the comparison between screened not referred and screened and referred groups. 
 b Unmarried, divorced, and widowed  
 c First- or second-degree relative  
 d Pills, injections, and patches    
                                                                                       Total screened women (8,278) Non-referred women (7,558)                                     Suspected and referred (720) 
                                                                                                   Median          SD  Median             SD                                            Median        SD   
Age (years)                                                                                  50                   8 50                     8        49                    7  
 Number           % Number             %    Number           %            aχ2 
Age groups                                                                                                                    
42 to 49 
50 to 69           
70+               
 
3793             46  
4257             51  
228              3 
 
3425             45 
3917             52 
              216               3 
 
       368               51 
       340               47 
     12                 2 
0.004 
 
Marital status  
                                                               Married           
                                                               Otherb            
 
            6501             79 
1777             21 
 
5960             79 
1598             21 
 
       541               75 
      179                25 
0.020 
Family history of cancer c  
                                                                          Yes                  
      No 
Missing                   
 
1736             21 
6420             79 
              122 
 
1561            21 
5883            79 
 
       175               25 
       537               75 
0.025 
Family history of breast cancer c  
Yes                  
No 
 Missing                                                                            
 
682              9 
7212             91 
              384 
 
598               8 
6592             92 
     84                12 
     620               88 
0.001 
 
Performed any breast self-examination                                                                
Yes                  
No 
 Missing                    
1554             19 
6427             81 
              297 
 
1412            19 
5865             81 
 
      142               20 
      562               80 
0.623 
Ever used a contraceptives method d                                                                
Yes                  
No                   
803              10 
7475             90 
 
734              10 
6824            90 
 
       69                 10 
      651               90 
                              
0.912 
 
History of surgical removal of ovaries (oophorectomy)  
Yes                  
No  
 Missing                  
 
309              4 
7858             96 
              111              
 
 
282              4 
7173           96 
 
 
       27                   4 
        685                 96 
0.990 
Any previous mammography                                                                
Yes                 
No 
 Missing                   
1463             18 
6547             82 
              268 
 
1294           18 
6010           82 
 
         169                24 
      537                76 
0.0001 
 Table 2. Characteristics of 8010 women seen at OCA with and without previous mammographic 
screening history in database of 2009-2016 
 
 
 
 
 
 
 
                                                                                        Previous mammography (1463) No previous mammography (6547) 
                                                                                                                                                                                                                                           Number % Number %                   χ2 
Age groups                                               
42 to 49                                 
50 to 69        
70+             
 
586      40 
847             58 
30             2 
 
3069             47 
3278             50 
200               3 
 <0.0001                                 
 
Marital status                                                       
 Married       
Other           
 
1163             79 
  300              21 
 
5116             78 
1431             22 
0.256 
 
Family history of cancer                                                           
 Yes           
No  
 Missing                             
 
487              34 
955              66 
             111 
 
1189            18 
5268            82 
<.0001 
 
Family history of breast cancer                                                         
 Yes            
No 
 Missing                              
268              19 
1159             81 
             157 
402              6 
6024            94 
 <.0001 
 
Preformed any breast self-examination                                                        
 Yes                   
No 
 Missing                                    
 
544              38 
899              62 
               65 
 
992             15 
5510           85 
 <.0001 
 
Ever used a contraceptives method                                                         
 Yes                   
No                                  
139              10 
1324      90   
 
634               10 
5913             90 
 0.831 
 
History of surgical removal of ovaries  
(oophorectomy)                  
Yes              
No  
 Missing                           
 
 
88               6 
1345             94 
             104 
 
 
222             3 
6251            97 
 <.0001 
 
 1 
 
Table 3. Odd ratio and 95% confidence interval from logistic regression of screening compliance 
among 8010 screened women at OCA during the period 2009-2016 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 OR 95% CI P value 
Age (years) 
                                               42 to 49  
                                               50 to 69 
                                               70+                                                                                 
 
0.64 
1.00 
0.57
 
0.56-0.72 
 
0.37-0.87
 
<.0001 
 
0.0102 
Family history of cancer  
Yes 
No 
 
1.55 
1.00 
 
1.32-1.82 
 
<.0001 
 
Breast self-examination 
Yes 
No 
 
3.16 
1.00 
 
2.77-3.61 
 
<.0001 
Family history of breast cancer  
Yes 
No                                                                                                                                                                                                                                   
 
2.10 
1.00
 
1.70-2.59 
 
 
<.0001 
 2 
 
 
Table 4. Recall rate, sensitivity, specificity, and positive predictive of the OCA screening 
programs during the period 2009-2016    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rate/ indicator   Number/percentage 
Number women recalled                              720 
Number of cancer detected  34 
Recall rate   9% 
Cancer detection rate (per 1000 screened women) 4.1 
Positive predictive value  4.7% 
Negative predictive value 99.6% 
Sensitivity 53% 
Specificity 92% 
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